Oral cryotherapy,
does it really help with Reduced WHO grade 3-4 severe oral mucositis?
research showsThe grade is C with 56 points. A four-arm trial randomized 160 patients and assessed 145. Severe oral mucositis occurred in 13.2% with ice throughout drug infusion versus 39.4% with usual oral care; the A-versus-D comparison had P=.011. The roughly 26-point absolute difference, an NNT near 4, was large, but a single sub-200-person center with unverified concealment, registration, and masking remains C evidence.
ads claimThe trial does not show that ice prevents every form of cancer-treatment mucositis. It tested schedules tied to specific conditioning-drug infusions.
Useful facts when choosing a product
- Four schedules were compared: whole infusion, second half, 15 minutes twice daily, and usual oral care.
- Severe mucositis was about 13.2% with whole-infusion cooling and 39.4% with usual care.
- No registration number was verified, and 145 of 160 randomized patients entered mucositis assessment.
Chamgap Semantic Classification Code
Candidate index · review held
M.cryotherapy-during-conditioning-drug-infusion-before-allogeneic-hematopoietic-stem-cell-transplantation.MULTI.who-grade-3-4-severe-oral-mucositis.reduce.usual-careMedicinal interventions > cryotherapy during conditioning-drug infusion before allogeneic hematopoietic stem-cell transplantation > Multiple: primary unresolved > WHO grade 3-4 severe oral mucositis > Reduction claim > Usual care
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The 2020 single-center four-arm randomized trial by Lu Y, Zhu X, Ma Q, Wang J, Jiang P, Teng S, Zhou L, Wu D, and Wang H enrolled 160 and assessed 145 patients through post-transplant day 15: 38, 36, 36, and 35 per arm. Cooling covered the full infusion, the second half, twice daily for 15 minutes, or was omitted under usual oral care. Severe mucositis was about 13.2%, 19.4%, 41.7%, and 39.4%; A versus D P=.011, B versus D P=.068, and C versus D P=.848. Funding from the Suzhou Municipal Science and Technology Bureau, SYSD2016083, was verified; no trial registration number was verified.
Why this is classified as C (56)
A large publicly funded difference in a clinical complication was limited by one small center and incomplete reporting of allocation, registration, and outcome hierarchy, giving C with 56 points.
Counterpoint. Cold intolerance, dental sensitivity, nausea, and swallowing difficulty may make prolonged cryotherapy unsuitable for some patients.
Rejudgment record. Cross-check applied — Cross-checked 160 randomized, 145 assessed, severe-mucositis rates and P values across four schedules, and public funding against the original bibliographic record and accessible original-study summaries
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of severe mucositis with whole-infusion cryotherapy | C | Rates were about 13.2% versus 39.4%, P=.011. |
| Cryotherapy for 15 minutes twice daily | D | It did not differ from usual care, P=.848. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Lu Y, Zhu X, Ma Q, Wang J, Jiang P, Teng S, Zhou L, Wu D, Wang H. 2020 | Single-center four-arm prospective randomized trial | 160 randomized; 145 assessed for mucositis, 38/36/36/35 | Suzhou Municipal Science and Technology Bureau, SYSD2016083 | Severe oral mucositis and duration through post-transplant day 15 | Severe mucositis about 13.2%, 19.4%, 41.7%, and 39.4%; A versus D P=.011 | Large publicly funded event-rate difference from one small trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-15).
Final verification and publication gate: Codex · Evidence date: 2026-08-15 · Corrections: none
Cite this verdict
[Chamgap] Oral cryotherapy x severe mucositis during allogeneic HSCT — Evidence Grade C·56. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/oral-cryotherapy-allogeneic-hsct-severe-mucositis/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.